Cargando…
1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States
BACKGROUND: PCVs have been recommended for U.S. children since 2000. A 7-valent vaccine (PCV7) was introduced in 2000. This was replaced by a 13-valent vaccine (PCV13) in 2010. PCV13 was also recommended for adults aged ≥ 65 years in August 2014. We evaluated PCV impact on IPD. METHODS: IPD cases (i...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777437/ http://dx.doi.org/10.1093/ofid/ofaa439.1651 |
_version_ | 1783630901475803136 |
---|---|
author | Pilishvili, Tamara Gierke, Ryan Farley, Monica M Schaffner, William Thomas, Ann Reingold, Art Harrison, Lee Holtzman, Corinne Burzlaff, Kari Petit, Susan Herlihy, Rachel Torres, Salina Beall, Bernard |
author_facet | Pilishvili, Tamara Gierke, Ryan Farley, Monica M Schaffner, William Thomas, Ann Reingold, Art Harrison, Lee Holtzman, Corinne Burzlaff, Kari Petit, Susan Herlihy, Rachel Torres, Salina Beall, Bernard |
author_sort | Pilishvili, Tamara |
collection | PubMed |
description | BACKGROUND: PCVs have been recommended for U.S. children since 2000. A 7-valent vaccine (PCV7) was introduced in 2000. This was replaced by a 13-valent vaccine (PCV13) in 2010. PCV13 was also recommended for adults aged ≥ 65 years in August 2014. We evaluated PCV impact on IPD. METHODS: IPD cases (isolation of pneumococcus from sterile sites) were identified through CDC’s Active Bacterial Core surveillance during 1998-2018. Isolates were serotyped by Quellung or whole genome sequencing and classified as PCV13-type and non-vaccine-type (NVT). Incidence rates (cases/100,000) were calculated using U.S. Census Bureau population denominators. RESULTS: From 1998 through 2018, overall IPD rates among children aged < 5 years decreased by 93% (from 95 to 7 cases/100,000). PCV13-type IPD decreased by 98% (from 88 to 2 cases/100,000). Among adults aged ≥ 65 years, overall IPD rates decreased by 60% (from 61 to 25 cases/100,000). PCV13-type IPD rates declined 86% (from 46 to 7 cases/100,000). Declines were most dramatic in the years following PCV7 introduction, with additional declines after PCV13 introduction in children (Figures 1 and 2). Serotypes 3, 19A, and 19F caused most of the remaining PCV13-type IPD. NVT IPD rates did not change significantly among children. Among adults aged 50-64 years, NVT IPD increased by 83% (from 6 to 12 cases/100,000) (p< 0.01). Among adults aged ≥ 65 years, NVT IPD increased by 22% (from 15 to 18 cases/100,000) (p< 0.01). The most common NVTs in 2018 were 22F (10% of all IPD), 9N (7%) and 15A (5%). Among children, the proportion of cases with meningitis increased from 5% to 14% (p< 0.01), and the proportion with pneumonia/empyema increased from 17% to 31% (p< 0.01). Among adults, the proportion of cases with meningitis did not change (3%), while the proportion with pneumonia/empyema increased from 72% to 76% (p=0.01). Figure 1: Incidence of invasive pneumococcal disease among children aged < 5 years, 1998-2018 [Image: see text] Figure 2: Incidence of invasive pneumococcal disease among adults aged ≥ 65 years, 1998-2018 CONCLUSION: Overall IPD incidence among children and adults decreased following PCV introduction for children, driven primarily by reductions in PCV-type IPD. NVT IPD increased in older adults, but these increases did not eliminate reductions from PCV13-type IPD. [Image: see text] DISCLOSURES: Lee Harrison, MD, GSK (Consultant)Merck (Consultant)Pfizer (Consultant)Sanofi Pasteur (Consultant) |
format | Online Article Text |
id | pubmed-7777437 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77774372021-01-07 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States Pilishvili, Tamara Gierke, Ryan Farley, Monica M Schaffner, William Thomas, Ann Reingold, Art Harrison, Lee Holtzman, Corinne Burzlaff, Kari Petit, Susan Herlihy, Rachel Torres, Salina Beall, Bernard Open Forum Infect Dis Poster Abstracts BACKGROUND: PCVs have been recommended for U.S. children since 2000. A 7-valent vaccine (PCV7) was introduced in 2000. This was replaced by a 13-valent vaccine (PCV13) in 2010. PCV13 was also recommended for adults aged ≥ 65 years in August 2014. We evaluated PCV impact on IPD. METHODS: IPD cases (isolation of pneumococcus from sterile sites) were identified through CDC’s Active Bacterial Core surveillance during 1998-2018. Isolates were serotyped by Quellung or whole genome sequencing and classified as PCV13-type and non-vaccine-type (NVT). Incidence rates (cases/100,000) were calculated using U.S. Census Bureau population denominators. RESULTS: From 1998 through 2018, overall IPD rates among children aged < 5 years decreased by 93% (from 95 to 7 cases/100,000). PCV13-type IPD decreased by 98% (from 88 to 2 cases/100,000). Among adults aged ≥ 65 years, overall IPD rates decreased by 60% (from 61 to 25 cases/100,000). PCV13-type IPD rates declined 86% (from 46 to 7 cases/100,000). Declines were most dramatic in the years following PCV7 introduction, with additional declines after PCV13 introduction in children (Figures 1 and 2). Serotypes 3, 19A, and 19F caused most of the remaining PCV13-type IPD. NVT IPD rates did not change significantly among children. Among adults aged 50-64 years, NVT IPD increased by 83% (from 6 to 12 cases/100,000) (p< 0.01). Among adults aged ≥ 65 years, NVT IPD increased by 22% (from 15 to 18 cases/100,000) (p< 0.01). The most common NVTs in 2018 were 22F (10% of all IPD), 9N (7%) and 15A (5%). Among children, the proportion of cases with meningitis increased from 5% to 14% (p< 0.01), and the proportion with pneumonia/empyema increased from 17% to 31% (p< 0.01). Among adults, the proportion of cases with meningitis did not change (3%), while the proportion with pneumonia/empyema increased from 72% to 76% (p=0.01). Figure 1: Incidence of invasive pneumococcal disease among children aged < 5 years, 1998-2018 [Image: see text] Figure 2: Incidence of invasive pneumococcal disease among adults aged ≥ 65 years, 1998-2018 CONCLUSION: Overall IPD incidence among children and adults decreased following PCV introduction for children, driven primarily by reductions in PCV-type IPD. NVT IPD increased in older adults, but these increases did not eliminate reductions from PCV13-type IPD. [Image: see text] DISCLOSURES: Lee Harrison, MD, GSK (Consultant)Merck (Consultant)Pfizer (Consultant)Sanofi Pasteur (Consultant) Oxford University Press 2020-12-31 /pmc/articles/PMC7777437/ http://dx.doi.org/10.1093/ofid/ofaa439.1651 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Poster Abstracts Pilishvili, Tamara Gierke, Ryan Farley, Monica M Schaffner, William Thomas, Ann Reingold, Art Harrison, Lee Holtzman, Corinne Burzlaff, Kari Petit, Susan Herlihy, Rachel Torres, Salina Beall, Bernard 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States |
title | 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States |
title_full | 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States |
title_fullStr | 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States |
title_full_unstemmed | 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States |
title_short | 1470. Epidemiology of Invasive Pneumococcal Disease (IPD) Following 18 years of Pneumococcal Conjugate Vaccine (PCV) Use in the United States |
title_sort | 1470. epidemiology of invasive pneumococcal disease (ipd) following 18 years of pneumococcal conjugate vaccine (pcv) use in the united states |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777437/ http://dx.doi.org/10.1093/ofid/ofaa439.1651 |
work_keys_str_mv | AT pilishvilitamara 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates AT gierkeryan 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates AT farleymonicam 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates AT schaffnerwilliam 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates AT thomasann 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates AT reingoldart 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates AT harrisonlee 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates AT holtzmancorinne 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates AT burzlaffkari 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates AT petitsusan 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates AT herlihyrachel 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates AT torressalina 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates AT beallbernard 1470epidemiologyofinvasivepneumococcaldiseaseipdfollowing18yearsofpneumococcalconjugatevaccinepcvuseintheunitedstates |